PBH
Prestige Consumer Healthcare
NYSE · Pharmaceuticals
$66.33
+0.78 (+1.19%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 1.09B | 1.08B | 512.07M | 462.83M | 441.46M |
| Net Income | 206.05M | 182.63M | 114.75M | 138.88M | 138.12M |
| EPS | — | — | — | — | — |
| Profit Margin | 18.9% | 17.9% | 22.4% | 30.0% | 31.3% |
| Rev Growth | +1.5% | +1.5% | +24.0% | +15.0% | +3.5% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 568.12M | 568.12M | 1.37B | 1.29B | 1.07B |
| Total Equity | 1.03B | 1.03B | 1.84B | 1.56B | 1.69B |
| D/E Ratio | 0.55 | 0.55 | 0.75 | 0.82 | 0.63 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | 339.04M | 317.20M | 225.09M | 217.92M | 202.17M |
| Free Cash Flow | — | — | 99.79M | 109.94M | 68.20M |